The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
SciSparc Signs Definitive Agreement to Sell MitoCareX to N2OFF
Mar 03, 2025•over 1 year ago
Contract Type
agreement
Tel AvivHealthcareHealth Care
Description
SciSparc has signed a definitive agreement to sell its entire ownership interest in MitoCareX Bio Ltd. to N2OFF, a publicly-traded company in the United States. The agreement involves the sale of MitoCareX's shares for $700,000 and the exchange of remaining shares for common stock in N2OFF.
Company Information
Company
SciSparc Ltd
Location
20 RAUL WALLENBERG STREET, TOWER A
Tel Aviv, Tel Aviv District, Israel
About
SciSparc is a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapies. The company aims to leverage cutting-edge technology to improve patient outcomes. SciSparc is involved in various pharmaceutical developments and partnerships to enhance its product pipeline.
Tel AvivHealthcareHealth Care